This clinical trial is a Phase 1 study evaluating the safety of LAM-003 when administered to men and women with previously treated relapsed or refractory AML. Currently, there is a great unmet need for treating AML that has either not responded to or returned after other treatments. Based on laboratory and animal studies, it appears that LAM-003 may block some of the cell signals that cause AML to grow.
Subjects will self-administer oral LAM-003 QD or BID continuously in repeated 28-day cycles. The amount of time each subject spends on study will vary significantly but on average time on study is expected to be approximately 4-6 months.
Subjects will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects. Study participants will be compensated for their time.